GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Update

Posted by on Jul 13th, 2026

GeoVax Labs Inc. (NASDAQ:GOVX – Get Free Report) saw a large decline in short interest in June. As of June 30th, there was short interest totaling 62,850 shares, a decline of 76.9% from the June 15th total of 271,752 shares. Based on an average daily trading volume, of 436,362 shares, the short-interest ratio is currently 0.1 days. Currently, 1.8% of the shares of the stock are sold short.

GeoVax Labs Stock Performance

Shares of GeoVax Labs stock traded down $0.07 during trading hours on Monday, reaching $1.11. 306,057 shares of the company were exchanged, compared to its average volume of 356,370. GeoVax Labs has a 1 year low of $0.96 and a 1 year high of $23.10. The stock’s fifty day moving average is $1.65 and its 200 day moving average is $2.08. The firm has a market cap of $3.85 million, a PE ratio of -0.06 and a beta of 3.68.

GeoVax Labs (NASDAQ:GOVX – Get Free Report) last released its earnings results on Wednesday, April 15th. The company reported $1.85 earnings per share (EPS) for the quarter. Research analysts expect that GeoVax Labs will post -8.69 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on GOVX. Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a research note on Sunday, June 21st. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a report on Tuesday, April 21st. Finally, D. Boral Capital restated a “hold” rating on shares of GeoVax Labs in a report on Thursday, April 16th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, GeoVax Labs has a consensus rating of “Reduce” and a consensus price target of $150.00.

Read Our Latest Analysis on GOVX

Hedge Funds Weigh In On GeoVax Labs

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new stake in shares of GeoVax Labs during the first quarter worth approximately $27,000. HRT Financial LP acquired a new stake in GeoVax Labs in the fourth quarter valued at approximately $31,000. Armistice Capital LLC purchased a new position in GeoVax Labs in the third quarter worth approximately $253,000. Renaissance Technologies LLC purchased a new position in GeoVax Labs in the fourth quarter worth approximately $104,000. Finally, Hudson Bay Capital Management LP acquired a new position in GeoVax Labs during the 3rd quarter worth approximately $47,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

(Get Free Report)

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.

Featured Stories

Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.